Relates to dihydropyrimidine dehydrogenase deficiency testing
Summary
Requires dihydropyrimidine dehydrogenase deficiency testing prior to fluoropyrmidine or other antimetabolite treatment; requires policies and contracts of insurance to include coverage for dihydropyrimidine dehydrogenase deficiency testing; provides for dihydropyrimidine dehydrogenase deficiency testing under the medical assistance program.
Bill status
in committee
1 of 4 stages cleared
Introduction
May 2019
Committee Review
Floor Vote
Governor
Introduced May 9, 2019
Last action Jan 8, 2020
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
2
Key actions
0
Committee
2
Jan 8, 2020
Assembly · Referred to committee
REFERRED TO HEALTH
May 9, 2019
Assembly · Referred to committee
REFERRED TO HEALTH
1 primary · 0 co-sponsors
Sponsors
Role
Legislator
Party
State
District
P
Pat Fahy
DDemocratic
Ask Maddy
·
AI policy assistant
Ask Maddy about A 7533
Scope: NY
Hi! I can help you understand A 7533. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline